JonesResearch analyst Catherine Novack initiated coverage of Rezolute with a Buy rating and $10 price target. The analyst says Rezolute is an “under-appreciated player in the rare disease space,” with its lead asset RZ358 in Phase 3 for congenital hyperinsulinism, a disease that causes life-threatening low blood sugar in children and infants. The firm sees growing value in label expansion, saying RZ358 can mitigate hypoglycemia caused by some rare tumors, and pivotal studies could start as early as 2025. Its 2030 global sales estimate for RZ358 indications combined is $650M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute initiated with a Buy at Maxim
- Rezolute’s Preclinical Success with New Hypoglycemia Treatment
- Rezolute reports validation of potential use of RZ358
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
- Rezolute participates in a conference call with Cantor Fitzgerald